Results 1 to 10 of about 576 (142)

Mycophenolate mofetil (MMF) in the treatment of epidermolysis bullosa acquisita (EBA) long-term follow-up [PDF]

JAAD Case Reports, 2015
Epidermolysis bullosa acquisita (EBA) is an autoimmune mucocutaneous blistering disease.1, 2 Cutaneous involvement presents with blisters primarily on trauma-prone areas healing with milia.1, 2 Mucosal involvement can lead to irreversible scarring. The treatment of EBA is based on anecdotal reports in the literature with systemic therapies.3, 4, 5, 6 ...
Naveed Sami
exaly   +4 more sources

Case report: Epidermolysis bullosa acquisita following dipeptidyl peptidase-4 inhibitor therapy and complicated by immune thrombocytopenic purpura [PDF]

Frontiers in Immunology
Epidermolysis bullosa acquisita (EBA) is a rare autoimmune blistering disease caused by autoantibodies to type VII collagen. While dipeptidyl peptidase-4 (DPP-4) inhibitors are established triggers for bullous pemphigoid (BP), their association with EBA ...
Hirofumi Kawamoto, Natsuko Sasaki, Yukimi Ueda, Norito Ishii, Yu Sawada   +4 more
doaj   +2 more sources

Complexities of care in a pediatric patient with epidermolysis bullosa acquisita and duchenne muscular dystrophy: a case report [PDF]

Journal of Medical Case Reports
Background Type VII collagen autoantibodies drive epidermolysis bullosa acquisita (EBA), a rare autoimmune blistering disorder. While typically seen in adults, pediatric cases—especially those with additional comorbidities—present unique clinical ...
Khayry Al-Shami, Ziad Haddad, Malath Mohammad Yousef Abuelrub, Basel Adnan Adel Qaddoumi, Falah Qudah, Tala Abdelaziz Abdullateef Shandaq, Manar Al-Shami, Saja Karaja   +7 more
doaj   +2 more sources

An Exceedingly Rare Case of Mechanobullous Epidermolysis Bullosa Acquisita in a Prepubertal Child: A Review of the Clinical and Laboratory Considerations [PDF]

Antibodies
Introduction: Epidermolysis bullosa acquisita (EBA) is a rare autoimmune disease causing subepithelial blistering due to autoantibodies against type VII collagen.
Aleksandra Wiktoria Bratborska, Maciej Spałek, Monika Bowszyc-Dmochowska, Marian Dmochowski   +3 more
doaj   +2 more sources

C-type lectin receptor expression is a hallmark of neutrophils infiltrating the skin in epidermolysis bullosa acquisita [PDF]

Frontiers in Immunology, 2023
IntroductionInflammatory epidermolysis bullosa acquisita (EBA) is characterized by a neutrophilic response to anti-type VII collagen (COL7) antibodies resulting in the development of skin inflammation and blistering.
Christian F. Guerrero-Juarez, Christian F. Guerrero-Juarez, Paul Schilf, Jing Li, Maria Paula Zappia, Lei Bao, Payal M. Patel, Payal M. Patel, Jenny Gieseler-Tillmann, Sripriya Murthy, Connor Cole, Maria Sverdlov, Maxim V. Frolov, Takashi Hashimoto, Norito Ishii, Thomas Rülicke, Katja Bieber, Katja Bieber, Ralf J. Ludwig, Ralf J. Ludwig, Christian D. Sadik, Kyle T. Amber, Kyle T. Amber   +22 more
doaj   +2 more sources

The Retinoid Tamibarotene Aggravates Skin Inflammation in a Model of Bullous Pemphigoid-like Epidermolysis Bullosa Acquisita [PDF]

Cells
Tamibarotene (AM80) is an agonist of retinoic acid receptor alpha. It is licensed in Japan for the treatment of acute promyelocytic leukemia. Results from preclinical models suggest that tamibarotene might also be effective in the treatment of diverse ...
Markus Thieme, Paul Schilf, Sripriya Murthy, Sina Gonther, Christoph M. Hammers, Guido Heine, Christian D. Sadik   +6 more
doaj   +2 more sources

Clinical Features of Paediatric Inflammatory Epidermolysis Bullosa Acquisita: A Case Series Study [PDF]

Acta Dermato-Venereologica
Epidermolysis bullosa acquisita (EBA) rarely develops in childhood. This study retrospectively recruited paediatric patients with EBA (age ≤ 16 years), diagnosed by clinical and histopathological features and results of immunofluorescence, immunoblotting
Yuexin Zhang, Jingyang Dang, Ruoyu Li, Xixue Chen, Xuejun Zhu, Mingyue Wang   +5 more
doaj   +2 more sources

Inhibition of interferon gamma impairs induction of experimental epidermolysis bullosa acquisita [PDF]

Frontiers in Immunology
Epidermolysis bullosa acquisita (EBA) is a muco-cutaneous autoimmune disease characterized and caused by autoantibodies targeting type VII collagen (COL7). The treatment of EBA is notoriously difficult, with a median time to remission of 9 months.
Natalie Gross, Jana Marketon, Sadegh Mousavi, Kathrin Kalies, Ralf J. Ludwig, Ralf J. Ludwig, Katja Bieber   +6 more
doaj   +2 more sources

A Narrative Review of Pemphigoid Diseases: Bridging Associations, Comorbidities, and Management [PDF]

Dermatology and Therapy
Pemphigoid diseases are a group of rare, chronic autoimmune blistering disorders (AIBD) characterized by subepidermal blister formation due to autoantibody-mediated targeting of structural components of the basement membrane zone (BMZ).
Emma L. Myers, Donna A. Culton
doaj   +2 more sources

Selective Complement Inhibition in Anti-p200 Pemphigoid: Immune Infiltrate Profiles and Therapeutic Implications Compared to Bullous Pemphigoid [PDF]

Biomolecules
Anti-p200 pemphigoid is an autoimmune blistering disease (AIBD) caused by autoantibodies against laminin β4 and/or γ1, and clinically resembles bullous pemphigoid (BP) as well as the inflammatory variant of epidermolysis bullosa acquisita (EBA).
Shirin Emtenani, Tina Rastegar Lari, Charlotte Kiehne, Nina van Beek, Maike M. Holtsche, Enno Schmidt   +5 more
doaj   +2 more sources